No Association of Multiple Sclerosis with
Multiple Sclerosis (MS) is a common immune-mediated disorder of the central nervous system that affects young adults and is characterized by demyelination and neurodegeneration. Recent studies have as...
Protéine G cdc42 : Questions médicales fréquentes
Questions fréquentes et termes MeSH associés
Diagnostic 5
#1
Comment diagnostiquer une dysfonction de cdc42 ?
Des tests génétiques et des analyses de signalisation cellulaire peuvent être utilisés.
#2
Quels tests sont utilisés pour cdc42 ?
Les tests incluent l'immunoblotting et la microscopie à fluorescence.
#3
Y a-t-il des biomarqueurs pour cdc42 ?
Actuellement, il n'existe pas de biomarqueurs spécifiques pour cdc42.
#4
Quels symptômes indiquent un problème avec cdc42 ?
Des anomalies dans la migration cellulaire et la morphogenèse peuvent être observées.
#5
Peut-on détecter cdc42 dans des échantillons biologiques ?
Oui, cdc42 peut être détecté dans des échantillons de tissus ou de cellules.
Symptômes 5
#1
Quels sont les symptômes d'une mutation de cdc42 ?
Les mutations peuvent entraîner des troubles de la migration cellulaire et des malformations.
#2
Comment cdc42 affecte-t-il la cellule ?
Cdc42 régule la forme et le mouvement des cellules, influençant leur fonction.
#3
Y a-t-il des signes cliniques associés à cdc42 ?
Des anomalies dans le développement et la motilité cellulaire peuvent être observées.
#4
Cdc42 est-il lié à des maladies spécifiques ?
Oui, des anomalies de cdc42 sont associées à des cancers et des maladies génétiques.
#5
Quels effets cdc42 a-t-il sur le cytosquelette ?
Cdc42 joue un rôle clé dans la régulation du cytosquelette, influençant la forme cellulaire.
Prévention 5
#1
Peut-on prévenir les mutations de cdc42 ?
La prévention des mutations génétiques est complexe et dépend de facteurs environnementaux.
#2
Y a-t-il des mesures préventives pour les maladies liées à cdc42 ?
Des conseils génétiques peuvent aider à évaluer le risque de maladies liées à cdc42.
#3
Comment le mode de vie influence-t-il cdc42 ?
Un mode de vie sain peut réduire le risque de maladies associées à cdc42.
#4
Les tests génétiques peuvent-ils prévenir des problèmes avec cdc42 ?
Oui, les tests génétiques peuvent identifier les porteurs de mutations de cdc42.
#5
Y a-t-il des recommandations diététiques pour cdc42 ?
Une alimentation équilibrée peut soutenir la santé cellulaire, mais n'affecte pas directement cdc42.
Traitements 5
#1
Quels traitements ciblent cdc42 ?
Des inhibiteurs spécifiques de cdc42 sont en cours de développement pour le cancer.
#2
Peut-on utiliser des thérapies géniques pour cdc42 ?
La thérapie génique est une approche potentielle pour corriger les mutations de cdc42.
#3
Y a-t-il des médicaments pour moduler cdc42 ?
Des composés chimiques sont en cours d'évaluation pour moduler l'activité de cdc42.
#4
Comment la recherche avance-t-elle sur cdc42 ?
La recherche se concentre sur les inhibiteurs et les voies de signalisation associées.
#5
Les traitements sont-ils efficaces contre cdc42 ?
L'efficacité des traitements dépend du type de maladie et de la mutation spécifique.
Complications 5
#1
Quelles complications sont liées à cdc42 ?
Les complications incluent des troubles du développement et des cancers.
#2
Cdc42 peut-il entraîner des problèmes neurologiques ?
Des anomalies de cdc42 sont associées à des troubles neurologiques dans certains cas.
#3
Y a-t-il des complications à long terme avec cdc42 ?
Les complications à long terme peuvent inclure des cancers et des malformations congénitales.
#4
Comment cdc42 affecte-t-il le système immunitaire ?
Cdc42 peut influencer la réponse immunitaire, mais les effets varient selon les contextes.
#5
Les complications de cdc42 sont-elles réversibles ?
Certaines complications peuvent être gérées, mais d'autres peuvent être permanentes.
Facteurs de risque 5
#1
Quels sont les facteurs de risque pour cdc42 ?
Les facteurs incluent des prédispositions génétiques et des influences environnementales.
#2
L'exposition à des toxines affecte-t-elle cdc42 ?
Oui, certaines toxines environnementales peuvent influencer l'expression de cdc42.
#3
Les antécédents familiaux augmentent-ils le risque ?
Oui, des antécédents familiaux de maladies génétiques peuvent augmenter le risque.
#4
Le stress peut-il affecter cdc42 ?
Le stress peut influencer la signalisation cellulaire, y compris celle de cdc42.
#5
Y a-t-il des groupes à risque pour cdc42 ?
Les individus avec des mutations génétiques spécifiques sont à risque accru.
Contenu validé par Dr Olivier Menir
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 15/02/2025
Contenu vérifié selon les dernières recommandations médicales
Auteurs principaux
Jeong Woo Park
2 publications dans cette catégorie
Affiliations :
- Department of Biological Science, University of Ulsan, Ulsan, 44610, South Korea.
Publications dans "Protéine G cdc42" :
-
Developmentally regulated GTP-binding protein-2 regulates adipocyte differentiation.
Biochemical and biophysical research communications 2021-08-29
-
Developmentally regulated GTP-binding protein 2 levels in prostate cancer cell lines impact docetaxel-induced apoptosis.
Investigative and clinical urology
Ming Huang
2 publications dans cette catégorie
Affiliations :
- Environmental Toxicology Graduate Program, University of California, Riverside, Riverside, California 92521, United States.
Publications dans "Protéine G cdc42" :
-
Targeted Quantitative Profiling of GTP-Binding Proteins Associated with Metastasis of Melanoma Cells.
Journal of proteome research 2021-10-25
-
GLOBAL AND TARGETED PROFILING OF GTP-BINDING PROTEINS IN BIOLOGICAL SAMPLES BY MASS SPECTROMETRY.
Mass spectrometry reviews 2020-06-10
Yinsheng Wang
2 publications dans cette catégorie
Affiliations :
- Department of Chemistry, University of California, Riverside, Riverside, California 92521, United States.
- Environmental Toxicology Graduate Program, University of California, Riverside, Riverside, California 92521, United States.
Publications dans "Protéine G cdc42" :
-
Targeted Quantitative Profiling of GTP-Binding Proteins Associated with Metastasis of Melanoma Cells.
Journal of proteome research 2021-10-25
-
GLOBAL AND TARGETED PROFILING OF GTP-BINDING PROTEINS IN BIOLOGICAL SAMPLES BY MASS SPECTROMETRY.
Mass spectrometry reviews 2020-06-10
Natsumi Maruta
2 publications dans cette catégorie
Affiliations :
- Plant Genetic Engineering Laboratory, School of Agriculture and Food Sciences, University of Queensland, Brisbane, QLD, 4072, Australia.
- School of Chemistry and Molecular Biosciences, Institute for Molecular Bioscience and Australian Infectious Diseases Research Centre, University of Queensland, Brisbane, QLD 4072, Australia.
Publications dans "Protéine G cdc42" :
Yuri Trusov
2 publications dans cette catégorie
Affiliations :
- Plant Genetic Engineering Laboratory, School of Agriculture and Food Sciences, University of Queensland, Brisbane, QLD, 4072, Australia.
Publications dans "Protéine G cdc42" :
Daisuke Urano
2 publications dans cette catégorie
Affiliations :
- Temasek Life Sciences Laboratory, 1 Research Link, National University of Singapore, Singapore 117604, Singapore.
Publications dans "Protéine G cdc42" :
David Chakravorty
2 publications dans cette catégorie
Affiliations :
- Department of Biology, Pennsylvania State University, University Park, Pennsylvania 16802, USA.
Publications dans "Protéine G cdc42" :
Sarah M Assmann
2 publications dans cette catégorie
Affiliations :
- Department of Biology, Pennsylvania State University, University Park, Pennsylvania 16802, USA.
Publications dans "Protéine G cdc42" :
Jose R Botella
2 publications dans cette catégorie
Affiliations :
- Plant Genetic Engineering Laboratory, School of Agriculture and Food Sciences, University of Queensland, Brisbane, QLD, 4072, Australia.
Publications dans "Protéine G cdc42" :
Yang Wang
2 publications dans cette catégorie
Affiliations :
- State Key Laboratory of Crop Stress Biology for Arid Areas, College of Plant Protection, Northwest A&F University, Yangling, Shaanxi 712100, China.
Publications dans "Protéine G cdc42" :
-
The small GTP-binding protein TaRop10 interacts with TaTrxh9 and functions as a negative regulator of wheat resistance against the stripe rust.
Plant science : an international journal of experimental plant biology 2021-05-14
-
Regulation of dendrite growth by Cdc42 effector protein‑4 in hippocampal neurons
Molecular medicine reports 2022-02-16
Thomas Surrey
2 publications dans cette catégorie
Affiliations :
- Centre for Genomic Regulation (CRG), Department of Quantitative Cell Biology, The Barcelona Institute of Science and Technology (BIST), Carrer del Dr. Aiguader 88, 08003 Barcelona, Spain.
- Universitat Pompeu Fabra (UPF), Barcelona, Spain.
- Catalan Institution for Research and Advanced Studies (ICREA), Passeig Lluis Companys 23, Barcelona 08010, Spain.
Publications dans "Protéine G cdc42" :
-
Microtubule binding of the human augmin complex is directly controlled by importins and Ran-GTP.
Journal of cell science 2023-06-26
-
The speed of GTP hydrolysis determines GTP cap size and controls microtubule stability.
eLife 2020-02-13
Ti Wang
2 publications dans cette catégorie
Affiliations :
- The Hospital Affiliated to Medical School of Yangzhou University (Taizhou People's Hospital), Taizhou, Jiangsu, China; Cardiology Division, Emory University School of Medicine, Atlanta, GA, USA.
Publications dans "Protéine G cdc42" :
-
Estradiol-mediated small GTP-binding protein GDP dissociation stimulator induction contributes to sex differences in resilience to ferroptosis in takotsubo syndrome.
Redox biology 2023-11-16
-
Small GTP-binding protein GDP dissociation stimulator influences cisplatin-induced acute kidney injury via PERK-dependent ER stress.
Communications biology 2024-09-05
Ting Xiong
2 publications dans cette catégorie
Affiliations :
- Division of Cardiology, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, China.
Publications dans "Protéine G cdc42" :
-
Estradiol-mediated small GTP-binding protein GDP dissociation stimulator induction contributes to sex differences in resilience to ferroptosis in takotsubo syndrome.
Redox biology 2023-11-16
-
Small GTP-binding protein GDP dissociation stimulator influences cisplatin-induced acute kidney injury via PERK-dependent ER stress.
Communications biology 2024-09-05
Yuxue Yang
2 publications dans cette catégorie
Affiliations :
- The Hospital Affiliated to Medical School of Yangzhou University (Taizhou People's Hospital), Taizhou, Jiangsu, China.
Publications dans "Protéine G cdc42" :
-
Estradiol-mediated small GTP-binding protein GDP dissociation stimulator induction contributes to sex differences in resilience to ferroptosis in takotsubo syndrome.
Redox biology 2023-11-16
-
Small GTP-binding protein GDP dissociation stimulator influences cisplatin-induced acute kidney injury via PERK-dependent ER stress.
Communications biology 2024-09-05
Xiwei Chen
2 publications dans cette catégorie
Affiliations :
- The Hospital Affiliated to Medical School of Yangzhou University (Taizhou People's Hospital), Taizhou, Jiangsu, China.
Publications dans "Protéine G cdc42" :
-
Estradiol-mediated small GTP-binding protein GDP dissociation stimulator induction contributes to sex differences in resilience to ferroptosis in takotsubo syndrome.
Redox biology 2023-11-16
-
Small GTP-binding protein GDP dissociation stimulator influences cisplatin-induced acute kidney injury via PERK-dependent ER stress.
Communications biology 2024-09-05
Ziwei Ma
2 publications dans cette catégorie
Affiliations :
- Clinical Medical College, Dalian Medical University, Dalian, Liaoning, China.
Publications dans "Protéine G cdc42" :
-
Estradiol-mediated small GTP-binding protein GDP dissociation stimulator induction contributes to sex differences in resilience to ferroptosis in takotsubo syndrome.
Redox biology 2023-11-16
-
Small GTP-binding protein GDP dissociation stimulator influences cisplatin-induced acute kidney injury via PERK-dependent ER stress.
Communications biology 2024-09-05
Bangyun Zuo
2 publications dans cette catégorie
Affiliations :
- The Hospital Affiliated to Medical School of Yangzhou University (Taizhou People's Hospital), Taizhou, Jiangsu, China.
Publications dans "Protéine G cdc42" :
-
Estradiol-mediated small GTP-binding protein GDP dissociation stimulator induction contributes to sex differences in resilience to ferroptosis in takotsubo syndrome.
Redox biology 2023-11-16
-
Small GTP-binding protein GDP dissociation stimulator influences cisplatin-induced acute kidney injury via PERK-dependent ER stress.
Communications biology 2024-09-05
Dong Ning
2 publications dans cette catégorie
Affiliations :
- School of Medicine, National University of Ireland Galway, Galway, Ireland.
Publications dans "Protéine G cdc42" :
-
Estradiol-mediated small GTP-binding protein GDP dissociation stimulator induction contributes to sex differences in resilience to ferroptosis in takotsubo syndrome.
Redox biology 2023-11-16
-
Small GTP-binding protein GDP dissociation stimulator influences cisplatin-induced acute kidney injury via PERK-dependent ER stress.
Communications biology 2024-09-05
Ruilong Song
2 publications dans cette catégorie
Affiliations :
- College of Veterinary Medicine, Yangzhou University, Yangzhou, Jiangsu, China.
Publications dans "Protéine G cdc42" :
-
Estradiol-mediated small GTP-binding protein GDP dissociation stimulator induction contributes to sex differences in resilience to ferroptosis in takotsubo syndrome.
Redox biology 2023-11-16
-
Small GTP-binding protein GDP dissociation stimulator influences cisplatin-induced acute kidney injury via PERK-dependent ER stress.
Communications biology 2024-09-05
Xuesong Liu
2 publications dans cette catégorie
Affiliations :
- Department of Cardiology, The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China. Electronic address: seanxsl712@163.com.
Publications dans "Protéine G cdc42" :
-
Estradiol-mediated small GTP-binding protein GDP dissociation stimulator induction contributes to sex differences in resilience to ferroptosis in takotsubo syndrome.
Redox biology 2023-11-16
-
Small GTP-binding protein GDP dissociation stimulator influences cisplatin-induced acute kidney injury via PERK-dependent ER stress.
Communications biology 2024-09-05
Sources (10000 au total)
Ocrelizumab for multiple sclerosis.
Ocrelizumab is a humanised anti-CD20 monoclonal antibody developed for the treatment of multiple sclerosis (MS). It was approved by the Food and Drug Administration (FDA) in March 2017 for using in ad... To assess the benefits, harms, and tolerability of ocrelizumab in people with RRMS and PPMS.... We searched MEDLINE, Embase, CENTRAL, and two trials registers on 8 October 2021. We screened reference lists, contacted experts, and contacted the main authors of studies.... All randomised controlled trials (RCTs) involving adults diagnosed with RRMS or PPMS according to the McDonald criteria, comparing ocrelizumab alone or associated with other medications, at the approv... We used standard methodological procedures expected by Cochrane.... Four RCTs met our selection criteria. The overall population included 2551 participants; 1370 treated with ocrelizumab 600 mg and 1181 controls. Among the controls, 298 participants received placebo a... For people with RRMS, ocrelizumab probably results in a large reduction in relapse rate and little to no difference in adverse events when compared with interferon beta-1a at 96 weeks (moderate-certai...
Alemtuzumab for multiple sclerosis.
Multiple sclerosis (MS) is an autoimmune, T-cell-dependent, inflammatory, demyelinating disease of the central nervous system, with an unpredictable course. Current MS therapies focus on treating and ... To evaluate the benefits and harms of alemtuzumab alone or associated with other treatments in people with any form of MS.... We used standard, extensive Cochrane search methods. The latest search date was 21 June 2022.... We included randomized controlled trials (RCTs) in adults with any subtype of MS comparing alemtuzumab alone or associated with other medications versus placebo; another active drug; or alemtuzumab in... We used standard Cochrane methods. Our co-primary outcomes were 1. relapse-free survival, 2. sustained disease progression, and 3. number of participants experiencing at least one adverse event. Our s... We included three RCTs (1713 participants) comparing intravenous alemtuzumab versus subcutaneous interferon beta-1a for relapsing-remitting MS. Participants were treatment-naive (two studies) or had e... Compared with interferon beta-1a, alemtuzumab may improve relapse-free survival and sustained disease progression-free survival, and make little to no difference on the proportion of participants with...
[Multiple sclerosis treatments].
The last thirty years have led to the introduction of treatments that reduce the frequency of relapses and slow the progression of multiple sclerosis. They must be prescribed early, chosen according t...
Concurrent diagnoses of Tuberous sclerosis and multiple sclerosis.
Tuberous sclerosis (TS) is a monogenic disorder which causes disabling neurological symptoms. Similarly, multiple sclerosis (MS) may result in disability, but in contrast, is diagnosed without genetic...
Pregnancy and multiple sclerosis: 2022 recommendations from the French multiple sclerosis society.
The objective of this study was to develop evidence-based recommendations on pregnancy management for persons with multiple sclerosis (MS).... MS typically affects young women in their childbearing years. Increasing evidence is available to inform questions raised by MS patients and health professionals about pregnancy issues.... The French Group for Recommendations in Multiple Sclerosis (France4MS) reviewed PubMed and university databases (January 1975 through June 2021). The RAND/UCLA appropriateness method was developed to ... A strong agreement was reached for all 104 proposed recommendations. They cover diverse topics, such as pregnancy planning, follow-up during pregnancy and postpartum, delivery routes, locoregional ana... The 2022 recommendations of the French MS society should be helpful to harmonise counselling and treatment practice for pregnancy in persons with MS, allowing for better and individualised choices....
Ageing and multiple sclerosis.
The factor that is most relevant and strongly associated with the clinical course of multiple sclerosis is chronological age. Very young patients exclusively have relapsing remitting disease, whereas ...
Immunosenescence and multiple sclerosis.
Changes in the immune system associated with ageing are known as immunosenescence. This is characterised by a decline in immune response, chronic inflammation and an increased risk of autoimmune disea...
[Treatment of multiple sclerosis].
Multiple sclerosis is a chronic inflammatory disease of the central nervous system, caused by an autoimmune reaction. Treatment options have largely increased over the years. In this article, we prese...
Pediatric Multiple Sclerosis.
The current diagnostic criteria for pediatric onset multiple sclerosis (POMS) are summarized, as well as the evidence for performance of the most recent iteration of McDonald criteria in the pediatric...